{"nctId":"NCT00751881","briefTitle":"An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis","startDateStruct":{"date":"2008-08"},"conditions":["Multiple Sclerosis"],"count":1169,"armGroups":[{"label":"Teriflunomide 7 mg / 14 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Teriflunomide"]},{"label":"Teriflunomide 14 mg / 14 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Teriflunomide"]},{"label":"Placebo / Teriflunomide 14 mg","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Teriflunomide"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Teriflunomide","otherNames":["HMR1726"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Relapsing multiple sclerosis,\n* Two relapses in prior 2 years or one relapse in prior year.\n\nExclusion Criteria:\n\n* Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease,\n* Significantly impaired bone marrow function or, significant anemia, leukopenia or thrombocytopenia,\n* Pregnant or nursing woman,\n* Alcohol or drug abuse,\n* Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate,\n* Human immunodeficiency virus (HIV) positive,\n* Any known condition or circumstance that would prevent, in the investigator's opinion, compliance or completion of the study.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate","description":"ARR is obtained from the total number of confirmed relapses that occurred during the treatment period divided by the sum of treatment durations.\n\nEach episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in Expanded Disability Status Scale (EDSS) score or Functional System scores.\n\nTo account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as \"offset\" variable; treatment group, region of enrollment and baseline EDSS stratum as covariates).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.501","spread":null},{"groupId":"OG001","value":"0.389","spread":null},{"groupId":"OG002","value":"0.319","spread":null}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Time to Disability Progression","description":"Probability of disability progression at 24, 48, 108 and 132 weeks was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first 12-week sustained disability progression \\[i.e. increase from baseline of at least 1 point in EDSS score (at least 0.5 point for participants with baseline EDSS score \\>5.5) that persisted for at least 12 weeks\\].\n\nParticipants free of disability progression (no disability progression observed on treatment) were censored at the date of the last on-treatment EDSS evaluation.\n\nKaplan-Meier method consists in computing probabilities of non occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t. Probability of event at time t is 1 minus the probability of being event-free for the amount of time t.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"5.3","spread":null},{"groupId":"OG002","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"12.1","spread":null},{"groupId":"OG002","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":null},{"groupId":"OG001","value":"21.1","spread":null},{"groupId":"OG002","value":"15.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":null},{"groupId":"OG001","value":"22.2","spread":null},{"groupId":"OG002","value":"15.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Time Without Relapse","description":"Probability of no relapse at 24, 48, 108 and 132 weeks was estimated using Kaplan-Meier method on the time to relapse defined as the time from randomization to first EDSS confirmed relapse.\n\nParticipants free of confirmed relapse (no EDSS confirmed relapse observed on treatment) were censored at the date of the last study drug intake.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.4","spread":null},{"groupId":"OG001","value":"81.5","spread":null},{"groupId":"OG002","value":"85.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":null},{"groupId":"OG001","value":"71.9","spread":null},{"groupId":"OG002","value":"76.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.8","spread":null},{"groupId":"OG001","value":"58.2","spread":null},{"groupId":"OG002","value":"57.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":null},{"groupId":"OG001","value":"55.4","spread":null},{"groupId":"OG002","value":"51.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Change From Baseline to Week 48 in EDSS Total Score","description":"EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It consists of 8 ordinal rating scales assessing 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation.\n\nEDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS).\n\nBaseline adjusted least-squares means at Week 48 were estimated using a Mixed-effect model with repeated measures (MMRM) on EDSS score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors). All the timepoints from randomization up to Week 48 were included in the model.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.089","spread":"0.050"},{"groupId":"OG001","value":"0.042","spread":"0.049"},{"groupId":"OG002","value":"-0.050","spread":"0.052"}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Change From Baseline to Week 48 in Fatigue Impact Scale (FIS) Total Score","description":"FIS is a participants-reported scale that qualifies the impact of fatigue on daily life in participants with MS. It consists of 40 statements that measure fatigue in 3 areas; physical, cognitive, and social.\n\nFIS total score ranges from 0 (no problem) to 160 (extreme problem).\n\nBaseline adjusted least-squares means at week 48 were estimated using a Mixed-effect model with repeated measures (MMRM) on FIS total score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors). All the timepoints from randomization up to Week 48 were included in the model.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.669","spread":"1.576"},{"groupId":"OG001","value":"2.512","spread":"1.533"},{"groupId":"OG002","value":"1.915","spread":"1.628"}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Change From Baseline to Last Visit in Fatigue Impact Scale (FIS) Total Score","description":"Baseline adjusted least-squares means at last visit were estimated using an analysis of covariance (ANCOVA) model on collected data for FIS total score (treatment group, region of enrollment, baseline EDSS stratum, visit number for the last visit and baseline value as factors).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.311","spread":"1.671"},{"groupId":"OG001","value":"4.464","spread":"1.657"},{"groupId":"OG002","value":"2.043","spread":"1.682"}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Change From Baseline to Week 48 in Short Form Generic Health Survey - 36 Items (SF-36) Summary Scores","description":"SF-36 scale is a generic, self-administered, health-related quality-of-life (QOL) instrument. It is constructed such that the 36 questions represent 8 of the most important health concepts: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health.\n\nTwo summary scores are obtained:\n\n* the physical health component summary score,\n* the mental health component summary score.\n\nBoth scores range from 0 to 100 and a high score indicates a more favorable health state.\n\nBaseline adjusted least-squares means at week 48 were estimated using a Mixed-effect model with repeated measures \\[MMRM\\] on each summary score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors). All the timepoints from randomization up to Week 48 were included in the model.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.082","spread":"0.405"},{"groupId":"OG001","value":"-0.397","spread":"0.396"},{"groupId":"OG002","value":"-0.105","spread":"0.418"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.913","spread":"0.586"},{"groupId":"OG001","value":"-2.031","spread":"0.571"},{"groupId":"OG002","value":"-1.434","spread":"0.606"}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Change From Baseline to Last Visit in Short Form Generic Health Survey - 36 Items (SF-36) Summary Scores","description":"Baseline adjusted least-squares means at last visit were estimated using an analysis of covariance (ANCOVA) model on collected data for each summary score (treatment group, region of enrollment, baseline EDSS stratum, visit number for the last visit and baseline value as factors).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.629","spread":"0.435"},{"groupId":"OG001","value":"-0.909","spread":"0.441"},{"groupId":"OG002","value":"-0.638","spread":"0.436"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.792","spread":"0.592"},{"groupId":"OG001","value":"-1.704","spread":"0.597"},{"groupId":"OG002","value":"-1.087","spread":"0.593"}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Overview of Adverse Events","description":"Adverse Events (AE) are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"320","spread":null},{"groupId":"OG001","value":"344","spread":null},{"groupId":"OG002","value":"320","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Treatment Period: Overview of Treatment Emergent Adverse Events (TEAE)","description":"AEs were any unfavourable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"203","spread":null},{"groupId":"OG001","value":"200","spread":null},{"groupId":"OG002","value":"188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Treatment Period: Time to Disability Progression","description":"Probability of disability progression since the randomization of the core period was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first 12 week sustained disability progression \\[i.e. increase from baseline of at least 1 point in EDSS score (at least 0.5 point for participants with baseline EDSS score \\>5.5) that persisted for at least 12 weeks\\].\n\nParticipants free of disability progression (no disability progression observed on treatment) were censored at the date of the last on-treatment EDSS evaluation.\n\nKaplan-Meier method consists in computing probabilities of non occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event free for the amount of time t. Probability of event at time t was 1 minus the probability of being event-free for the amount of time t.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.130","spread":null},{"groupId":"OG001","value":"0.117","spread":null},{"groupId":"OG002","value":"0.077","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.190","spread":null},{"groupId":"OG001","value":"0.175","spread":null},{"groupId":"OG002","value":"0.147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.245","spread":null},{"groupId":"OG001","value":"0.233","spread":null},{"groupId":"OG002","value":"0.190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.307","spread":null},{"groupId":"OG001","value":"0.270","spread":null},{"groupId":"OG002","value":"0.248","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.328","spread":null},{"groupId":"OG001","value":"0.317","spread":null},{"groupId":"OG002","value":"0.265","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Treatment Period: ARR: Poisson Regression Estimate","description":"ARR was obtained from the total number of confirmed relapses that occurred during the treatment period divided by the sum of treatment durations. A relapse is defined as the appearance of a new clinical sign/symptom or clinical worsening of a previous sign/symptom (one that had been stable for at least 30 days) that persists for a minimum of 24 hours in the absence of fever. Relapse was confirmed by an increase in EDSS score or Functional System scores. To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as \"offset\" variable; treatment group, region of enrolment and baseline EDSS stratum as covariates).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.199","spread":null},{"groupId":"OG001","value":"0.200","spread":null},{"groupId":"OG002","value":"0.179","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Core Treatment Period: Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA)","description":"PCSA values are abnormal values considered medically important by the Sponsor according to predefined criteria based on literature review.\n\nHepatic parameters thresholds were defined as follows:\n\n* Alanine Aminotransferase (ALT) \\>3, 5, 10 or 20 upper limit of normal(ULN);\n* Aspartate aminotransferase (AST) \\>3, 5, 10 or 20 ULN;\n* Alkaline Phosphatase \\>1.5 ULN;\n* Total Bilirubin (TB) \\>1.5 or 2 ULN;\n* ALT \\>3 ULN and TB \\>2 ULN.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":385},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Alanine aminotransferase increased","Alopecia"]}}}